AC Immune S.A.
ACIU
Rank in Stocks
#15692
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to... AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Share Price
$2.44
Last synced: 2026-11-09
Market Cap
$248.33M
Change (1 day)
9.42%
Change (1 year)
-28.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AC Immune S.A. (ACIU)
Category
Healthcare
EPS for AC Immune S.A. (ACIU)
EPS as of September 2026 TTM: $-0.48
According to AC Immune S.A.'s latest financial reports, its current EPS (TTM) is $-0.48. At the end of 2025 the company had an EPS of $-0.88, a decrease compared to its 2024 EPS of $-0.56.
EPS history for AC Immune S.A. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.48 | -45.13% |
| 2025 | $-0.88 | 56.23% |
| 2024 | $-0.56 | -25.81% |
| 2023 | $-0.76 | -17.23% |
| 2022 | $-0.92 | -13.58% |
| 2021 | $-1.06 | 11.12% |
| 2020 | $-0.96 | -244.71% |
| 2019 | $0.66 | -179.38% |
| 2018 | $-0.83 | 76.59% |
| 2017 | $-0.47 | 243.02% |
| 2016 | $-0.14 | -137.17% |
| 2015 | $0.37 | 93.52% |
| 2014 | $0.19 | -160.96% |
| 2013 | $-0.31 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,342.91% |
US
|
|
| $-7.07 | 1,364.07% |
US
|
|
| $-5.29 | 995.46% |
AU
|
|
| $12.88 | -2,767.24% |
BE
|
|
| $21.56 | -4,564.69% |
NL
|
Questions about AC Immune S.A.'s earnings per share (EPS)
What is AC Immune S.A.'s earnings per share (EPS)?
AC Immune S.A.'s earnings per share (EPS) over the last twelve months is $-0.48, as of Sep 2026.
What was AC Immune S.A.'s earnings per share (EPS) in 2025?
In 2025, AC Immune S.A.'s earnings per share (EPS) was $-0.88, compared with $-0.56 in 2024.
How has AC Immune S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, AC Immune S.A.'s earnings per share (EPS) was highest in 2024 ($-0.56) and lowest in 2021 ($-1.06).
How does AC Immune S.A.'s earnings per share (EPS) compare with similar companies?
AC Immune S.A.'s earnings per share (EPS) ($-0.48) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.